GDTC

CytoMed Therapeutics Ltd GDTC

NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $0.3M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Revenue

$324.4K

Quarter to Dec 31

Net income

$-3.98M

Quarter to Dec 31

Free cash flow

$-4.34M

Quarter to Dec 31

Top Institutional Holders

as of Q2 2026
$12.2K total
Axiom Investment Management LLC
$7.2KNew
UBS Group AG
$5.0K-21.9%
OSAIC HOLDINGS, INC.
$210.0%
See all 3 institutional holders →
Reading the latest SEC filing…

Key Metrics

Revenue

FY 2025
EDGAR

Net Income

FY 2025
EDGAR

EPS (Diluted)

FY 2025
EDGAR

ROIC

FY 2025
EDGAR

Free Cash Flow

FY 2025
EDGAR

Loading ratio trend…

GDTC key financials by period

Reported revenue, net income and operating margin by fiscal year, from CytoMed Therapeutics Ltd's annual filings on SEC EDGAR.

CytoMed Therapeutics Ltd reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2025$324.4K$-4.0M—
FY 2024$69.5K$-2.5M—
Source: GDTC filings on SEC EDGAR →

GDTC insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About CytoMed Therapeutics Ltd (GDTC): stock profile, AI score and financials

CytoMed Therapeutics Ltd (GDTC) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. GDTC is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.3m in revenue and is scored on the micro-cap board instead. Based on the latest XBRL financial filings (FY 2025), CytoMed Therapeutics Ltd reports quarterly revenue of $324.4K, net income of $-4.0M, free cash flow of $-4.3M. Top institutional holders of GDTC by reported 13-F value include Axiom Investment Management, UBS Group AG, OSAIC, based on the most recent SEC filings. GDTC trades on the Nasdaq exchange and files with the SEC under CIK 1873093. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate GDTC daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for CytoMed Therapeutics Ltd directly from SEC EDGAR.

SEC EDGAR: CIK 1873093 →